A critical need for better cancer immunotherapy models: Are organotypic tumor spheroid cultures the answer?

Justin M. Balko*, Jeffrey A. Sosman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Immunotherapy has transformed the therapeutic landscape of cancer, but the preclinical evaluation of combination approaches that will deepen and broaden its clinical benefit has lagged far behind due to the lack of expedient and easily accessible ex vivo human systems. In this issue, Jenkins and colleagues and Deng and colleagues report the use of organotypic cultures of tumors derived from mice and humans containing both tumor cells and cells from their local immune microenvironment to recapitulate the in vivo use of immune checkpoint inhibitors and extend the application of this system to therapeutic combinations of immune checkpoint blockade and molecularly targeted agents.

Original languageEnglish (US)
Pages (from-to)143-145
Number of pages3
JournalCancer discovery
Volume8
Issue number2
DOIs
StatePublished - Feb 2018

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'A critical need for better cancer immunotherapy models: Are organotypic tumor spheroid cultures the answer?'. Together they form a unique fingerprint.

Cite this